Clinical Trial Detail

NCT ID NCT03426891
Title Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

malignant glioma

gliosarcoma

glioblastoma multiforme

Therapies

Pembrolizumab + Temozolomide + Vorinostat

Age Groups: adult senior

No variant requirements are available.